AI Drug Discovery for Pharma and Biotech

Drug discovery

2

drugs

With orphan designations

Overview

Diffuse alveolar hemorrhage (DAH) is a life-threatening syndrome marked by intra-alveolar bleeding, often secondary to autoimmune disorders (e.g., vasculitis, systemic lupus erythematosus), coagulation defects, infections, or toxins. Clinical hallmarks include dyspnea, hemoptysis, anemia, and diffuse pulmonary infiltrates. Diagnosis requires bronchoscopy with bronchoalveolar lavage showing progressively bloody fluid. Treatment focuses on immunosuppression (corticosteroids, cyclophosphamide, rituximab) for autoimmune causes, supportive respiratory care, and addressing underlying etiologies. Mortality remains high (20–50%), particularly with shock, renal failure, or delayed intervention [1][2][5][14].

Population

Primarily adults, but idiopathic pulmonary hemosiderosis affects children. Common in autoimmune disorders (ANCA-associated vasculitis, SLE) and post-hematopoietic stem cell transplant recipients [1][10][14].

Burden

  • In-hospital mortality: 20–50%, rising to 70% in mechanically ventilated patients [2][6][13].

  • Long-term morbidity includes pulmonary fibrosis (53% survivors) and hypertension (20%) [6][13].

  • Immunosuppression-related infections and renal failure worsen outcomes [2][6].

Therapies

  • High-dose corticosteroids (e.g., methylprednisolone) and immunosuppressants (cyclophosphamide, rituximab) [1][3][5].

  • Plasma exchange for Goodpasture syndrome or severe vasculitis [1][11].

  • Recombinant factor VIIa or antifibrinolytics in refractory cases; invasive ventilation for respiratory failure [3][7][11].

Categories: rare respiratory diseases

Research Papers

648 drug discovery papers about Diffuse alveolar hemorrhage, with 3 first-in-class emerging drug candidates forecasted to outperform the average preclinical success rate. Recent publications:

648 drug discovery papers about Diffuse alveolar hemorrhage, with 3 first-in-class emerging drug candidates forecasted to outperform the average preclinical success rate. Recent publications:

categories:

Small molecules

small molecules
2026-09-17 | Hydrocephalus and Diffuse Alveolar Hemorrhage as the Initial Manifestation of Systemic Lupus Erythematosus and Antiphospholipid Syndrome: A Case Report.

Systemic lupus erythematosus (SLE) is an autoimmune disease that can affect many systems, such as the central nervous system (CNS), cardiovascular, musculocutaneous, renal, and respiratory systems, etc. SLE can occur alone or in association with other autoimmune diseases, especially antiphospholipid syndrome (APS). Hydrocephalus and diffuse alveolar hemorrhage (DAH) are infrequent manifestations of SLE and APS and increase the risk of mortality and morbidity in these patients. A 48-year-old man was hospitalized due to fever, hemoptysis, and headache, which had not been examined for diagnosis and treatment for a long period of time because of his negligence. After imaging and autoimmune tests were performed, hydrocephalus and DAH were diagnosed as initial manifestations of SLE in association with APS according to the SLE/APS criteria. Additionally, lupus nephritis was confirmed via renal biopsy. The hydrocephalus was due to sigmoid sinus thrombosis in the context of a hypercoagulable state of SLE and APS. The initiation of steroid and immunosuppressive treatments has yielded positive results, negating the need for any invasive procedures. The coexistence of SLE and hydrocephalus, although uncommon, has been documented in the literature. Hydrocephalus, a rare complication of SLE, necessitates timely decision-making regarding treatment based on the patient's clinical symptoms and the degree of ventricular dilation, which may involve either conservative medical management or surgical procedures such as a VP shunt. In patients with multiorgan involvement, rheumatological and autoimmune diseases are among our most important differential diagnoses. Importantly, neurological symptoms, particularly headaches, should not be underestimated, even though they are commonly observed in patients with SLE or APS. A detailed medical history, a comprehensive examination, and strong clinical suspicion are essential when patients present with neurological symptoms, and physicians must consider autoimmune diseases in their differential diagnoses.

Open article ↗



2026-09-08 | Diffuse Alveolar Hemorrhage: A Rare and Life-Threatening Manifestation of Fat Embolism Syndrome

Fat embolism syndrome (FES) often occurs following a long bone fracture and typically manifests within 24–72 h as respiratory distress, petechiae, and neurological signs. Fat embolism associated diffuse alveolar hemorrhage (DAH) is a rare but potentially life-threatening pulmonary complication. Here, we present a case of a 22-year-old male with femur and mandibular fractures following trauma who developed progressive hypoxemia and hemoptysis on day 2 of trauma. Chest X-ray imaging revealed bilateral alveolar infiltrates, and bronchoscopy confirmed alveolar hemorrhage. The patient was placed on mechanical ventilation due to severe alveolar hemorrhage. Treatment was initiated with methylprednisolone, along with nebulization of adrenaline and tranexamic acid to control the bleeding. DAH secondary to FES should be suspected in trauma patients presenting with hemoptysis and hypoxemia. Early diagnosis and prompt administration of corticosteroids and antifibrinolytic therapy can significantly improve patient outcomes.

Open article ↗



2026-09-03 | Androgen-associated remodeling of pulmonary NK cells and sex-biased susceptibility in lupus-associated diffuse alveolar hemorrhage.

Diffuse alveolar hemorrhage (DAH) is a lethal, female-biased complication of systemic lupus erythematosus (SLE). While adaptive immunity is a known driver, the role of innate lymphoid cells (ILCs) in DAH and the contribution of sex hormones to this process remain unclear. To characterize pulmonary ILC remodeling during DAH and evaluate whether androgen signaling modulates natural killer (NK) cell homeostasis and disease severity. A pristane-induced DAH model was established in C57BL/6J and Rag2 -/- mice. Pulmonary ILCs were profiled by single-cell transcriptomics and flow cytometry. Baseline sex differences were compared between healthy humans and mice. In vivo interventions included male castration, female testosterone propionate (TP) administration, and antibody-mediated NK cell depletion. DAH was accompanied by a marked reduction in pulmonary NK cell frequency in both C57BL/6J and Rag2 -/- mice, indicating an innate feature independent of adaptive lymphocytes. DAH-associated NK cells displayed an activated but constrained state, showing increased expression of effector-associated genes Prf1 and Ifng, together with the inhibitory receptor gene Lag3. At baseline, healthy human females and female mice exhibited lower NK cell frequencies than males. While male castration did not significantly alter DAH severity, TP administration in females restored pulmonary NK cell dominance and significantly attenuated disease severity. NK cell depletion prior to challenge led to a trend toward more severe hemorrhage (p = 0.084). Pulmonary NK cells are reduced in a lupus-associated DAH model and may participate in disease development. Androgen treatment restores pulmonary NK cell predominance and attenuates DAH severity, supporting further investigation of strategies aimed at restoring or preserving pulmonary NK cell homeostasis and function as potential therapeutic approaches for DAH.

Open article ↗



2026-08-12 | Diffuse Alveolar Hemorrhage Following Trauma: A Diagnostic Dilemma With Rapid Steroid Response.

Diffuse alveolar hemorrhage (DAH) is a rare but potentially life-threatening pulmonary condition that, while classically linked to autoimmune disorders, can occur in the setting of trauma. We report the case of a 20-year-old male who sustained polytrauma following a road traffic accident and initially had a normal chest radiograph. On the fourth day of hospitalization, he developed acute hypoxemia with new bilateral alveolar infiltrates; high-resolution computed tomography revealed diffuse ground-glass opacities with septal thickening. Bronchoalveolar lavage demonstrated progressively hemorrhagic return across aliquots, confirming DAH. Autoimmune markers were largely negative, and in the absence of systemic features, a multifactorial etiology involving trauma-related injury and anticoagulant use was considered. High-dose intravenous corticosteroids produced rapid clinical and radiological recovery. This case underscores the importance of considering DAH in trauma patients presenting with unexplained hypoxemia and bilateral infiltrates, even without hemoptysis, where early bronchoscopy and prompt treatment can be lifesaving.

Open article ↗



2026-08-01 | Diffuse alveolar hemorrhage in ANCA-associated vasculitis: Current evidence and multimodal treatment approaches.

Diffuse alveolar hemorrhage (DAH) is a rare but life-threatening complication of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV), with management largely extrapolated from broader AAV and ARDS literature. We conducted a review of studies published between 2000 and 2025 evaluating treatments and outcomes in AAV-associated DAH, synthesizing evidence across immunosuppressive, plasmapheresis, hemostatic, respiratory and hemodynamic, and infection prevention strategies. Glucocorticoids combined with rituximab or cyclophosphamide induce remission in most patients, although optimal steroid tapering and comparative efficacy in severe, ventilated DAH remain uncertain. Avacopan improves sustained remission and renal recovery in severe AAV and appears to be a feasible steroid-sparing adjunct in early DAH series. Large randomized trials demonstrate no survival benefit of plasma exchange. Local hemostatic therapies may provide rapid bleeding control, but evidence is limited. Respiratory outcomes are driven by hypoxemia severity and need for invasive ventilation or extracorporeal support. Lastly, infection prevention measures are strongly supported.

Open article ↗



antibodies
2026-06-30 | Unilateral diffuse alveolar haemorrhage as an atypical presentation of PR3-ANCA-associated vasculitis: A case report.

Diffuse alveolar haemorrhage (DAH) is a life-threatening pulmonary manifestation of small-vessel vasculitis, most commonly associated with anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis. Unilateral DAH has been infrequently reported and may pose diagnostic challenges, as its radiological presentation can mimic pneumonia, pulmonary oedema, or localized haemorrhage. This atypical presentation may delay recognition of the underlying vasculitis and appropriate immunosuppressive therapy. We present a case of a woman in her thirties with previously diagnosed PR3-ANCA-associated vasculitis who presented with acute worsening of dyspnea (mMRC grade IV) and hemoptysis. Radiological assessments revealed extensive right-sided ground-glass opacities with areas of consolidation and minimal left lower lobe involvement. Bronchoscopy with sequential bronchoalveolar lavage (BAL) showed progressively haemorrhagic aliquots consistent with DAH. Laboratory investigations revealed anemia (Hb 7.1 mg/dL) and elevated serum creatinine (5.02 mg/dL). The patient developed type I respiratory failure requiring mechanical ventilation and hemodialysis. She was treated with pulse intravenous methylprednisolone followed by rituximab therapy, along with trimethoprim-sulfamethoxazole prophylaxis. The patient improved clinically, radiologically, and biochemically and was discharged on supplemental oxygen.

Open article ↗



2026-05-29 | Alveolar dysregulation of host response in pneumonia and ARDS: implications for immune modulation and infection.

Respiratory failure due to pneumonia and acute respiratory distress syndrome (ARDS) remains a major cause of morbidity and mortality in the intensive care unit. The alveolar compartment plays a central role in both pathogen clearance and tissue injury, yet its biology is poorly captured by systemic measurements. Growing evidence shows that dysregulation of alveolar host responses drives disease progression, shapes susceptibility to secondary infections, and influences recovery. Community-, hospital-, and ventilator-associated pneumonia differ in microbial drivers and host responses, but all share a pattern of localized inflammation. In most cases, pathogens are rapidly controlled following antimicrobial treatment, while alveolar inflammation persists. This persistence likely reflects self-reinforcing cycles between epithelial injury, neutrophil activity, and monocyte-macrophage dysfunction. Mechanical ventilation further disrupts local defenses, promoting microbial overgrowth and ventilator-associated pneumonia.In ARDS, diffuse alveolar damage initiates an early influx of neutrophils and monocyte-derived macrophages. Although peripheral blood has been used to identify systemic inflammatory subphenotypes, molecular signatures in the alveolar compartment often differ and may provide complementary biological information. Patients may diverge into distinct alveolar immune trajectories, ranging from sustained alveolar hyperinflammation to immune exhaustion. These divergent trajectories influence downstream repair, determining whether patients achieve epithelial recovery or develop fibrotic remodeling.Alveolar immune dysregulation also creates a permissive niche for viral and fungal pathogens. Pulmonary reactivation of herpes simplex virus or cytomegalovirus and fungal infections with Aspergillus frequently occur in critically ill patients and may reflect impaired local host defense. These processes are associated with prolonged mechanical ventilation and illustrate how impaired alveolar defenses may sustain injury and propagate complications. Pneumonia and ARDS share common pathways of alveolar immune dysregulation that are not adequately captured by systemic profiling alone. Integrating systemic and alveolar immune assessment, including their concordance and discordance, may improve patient stratification, facilitate identification of treatable traits, and support the development of more personalized, compartment-informed therapeutic strategies, including both immunomodulatory and pathogen-directed interventions. A more refined understanding of compartment-specific host responses will be key to advancing these approaches.

Open article ↗



2026-05-01 | A35-24 Coughing Up Clues: Diffuse Alveolar Hemorrhage Revealing a Hidden Vasculitis

Abstract Diffuse alveolar hemorrhage (DAH) is a condition characterized by widespread bleeding into the alveoli through disruption of the alveolar-capillary membrane. It usually presents with nonspecific symptoms such as cough, hemoptysis, and dyspnea. DAH is frequently associated with small-vessel vasculitides, such as microscopic polyangiitis (MPA). MPA is a systemic, necrotizing form of small-vessel vasculitis that causes endothelial inflammation and injury, particularly affecting the kidneys and respiratory tract. In MPA, decreased immune tolerance of myeloperoxidase (MPO) prompts the formation of myeloperoxidase-antineutrophil cytoplasmic antibodies (MPO-ANCA). In the setting of DAH, MPA leads to pulmonary capillaritis, necrosis of the alveolar septa causing structural degradation and hemorrhage. 25-year-old male presents to the ED with a 1-week history of hemoptysis and hematuria. Upon evaluation in the ED, patient was noted to be tachypneic and tachycardic requiring BiPAP for respiratory support. Initial workup was significant for AKI and acute anemia. Chest X-ray showed diffuse interstitial and alveolar opacities, initially thought to be infectious vs edematous in nature. Heparin was also briefly started for possible pulmonary embolism but was quickly discontinued following worsening anemia and hemoptysis. Bronchoscopy was performed in setting of worsening respiratory distress with bronchoalveolar lavage with grossly pure blood. Autoimmune panel was positive for rheumatoid factor and ANA. Given these results and presentation of hemoptysis with hematuria, nephrology was consulted for further evaluation of possible systemic vasculitis. Renal biopsy was performed which revealed crescentic glomerulonephritis with positive MPO antibodies concerning for a pauci-immune vasculitis consistent with microscopic polyangiitis. After establishing vasculitis as the underlying etiology, the patient was subsequently treated with high-dose methylprednisolone and rituximab infusions. Repeat imaging performed one month later demonstrated complete resolution of bilateral infiltrates.Diffuse alveolar hemorrhage (DAH) has a broad differential, including autoimmune, infectious, and drug-induced causes. Bronchoscopic or histological evaluation may be required to establish the underlying diagnosis. In cases of microscopic polyangiitis, DAH is often due to early pulmonary capillaritis. Initial chest imaging may mimic pneumonia, which can delay diagnosis. While uncommon, DAH due to vasculitis should remain on the differential in patients with hemoptysis and diffuse infiltrates, particularly when accompanied by renal dysfunction. First-line therapy for DAH due to MPA includes high-dose corticosteroids combined with immunosuppressive agents such as rituximab or cyclophosphamide. Prognosis of DAH varies widely and is closely tied to the underlying cause. In ANCA-associated vasculitis, 5-year all-cause mortality is estimated to approach 25 percent. This abstract is funded by: None

Open article ↗



2026-05-01 | A33-39 Breathing Blood in a Triple Threat: Pulmonary-Renal Catastrophe and Diffuse Alveolar Hemorrhage in Lupus Triggered by Covid-19

Abstract Introduction Pulmonary-renal syndrome (PRS) is one of the most catastrophic complications of systemic lupus erythematosus (SLE), driven by complement-mediated endothelial injury. Diffuse alveolar hemorrhage (DAH) is a life-threatening pulmonary emergency, with high mortality, characterized by bleeding into alveolar spaces from alveolar-capillary membrane disruption. DAH may be exacerbated by infections that trigger complement activation, particularly in underlying conditions such as SLE, atypical hemolytic uremic syndrome (aHUS), and thrombotic microangiopathy (TMA). We present the case of recurrent DAH secondary to complement-mediated aHUS flare triggered by coronavirus disease 2019 (COVID-19) in a patient with SLE, culminating in multi-organ failure, highlighting the challenges of managing overlapping immune dysregulation successfully treated with multimodal immunotherapy. Description A 31-year-old male with SLE complicated by Class IV lupus nephritis, TMA, and aHUS presented with acute fever, chills, and dyspnea. Upon arrival, he was in severe respiratory distress, hypoxemic (SpO2 70% on ambient air), febrile (101 °F), tachycardic (115 bpm), and hypotensive (83/61 mmHg). Point-of-care ultrasound revealed diffuse B-lines; chest radiograph showed right lower lung field haziness. Laboratory studies demonstrated acute kidney injury (creatinine 3.08 mg/dL), anemia (hemoglobin 11.8 g/dL), thrombocytopenia (platelets 72K/uL), and metabolic acidosis (pH 7.24, lactate 3.0 mmol/L). His respiratory status rapidly deteriorated requiring emergent intubation, complicated by a 4-minute pulseless electrical activity, with return of spontaneous circulation. In the intensive care unit, he developed multi-organ failure. Bronchoscopy with bronchoalveolar lavage confirmed DAH, consistent with prior episodes; this was attributed to PRS with an underlying aHUS flare exacerbating DAH. Infectious workup concurrently revealed COVID-19 pneumonia, E. coli bacteremia, and ESBL Klebsiella ventilator-associated pneumonia. He was treated with remdesivir and meropenem. Management of aHUS flare and PRS included aggressive immunomodulation: high-dose corticosteroids, plasma exchange, intravenous immunoglobulin, and eculizumab. Given history of refractory disease, additional immunosuppression with rituximab and cyclophosphamide were administered. He developed acute renal failure, requiring continuous renal replacement therapy for seven days, followed by complete renal and pulmonary recovery allowing successful extubation. Discussion What began as COVID-19 pneumonia unraveled into a deadly cascade of complement activation, endothelial injury, and diffuse hemorrhage, culminating in pulmonary-renal catastrophe. This case illustrates the challenges in managing DAH and PRS in patients with complement-mediated aHUS, where infection and immune overactivation coexist. While COVID-19 may have triggered the complement cascade, the key clinical challenge was balancing aggressive immunosuppression amid infection. Our patient’s successful recovery highlights the importance of multimodal immunotherapy and early recognition of complement dysregulation to prevent irreversible pulmonary-renal damage. This abstract is funded by: None

Open article ↗



2026-05-01 | B35-53 Antiphospholipid Syndrome-associated Pulmonary Capillaritis Causing Diffuse Alveolar Hemorrhage: Sustained Steroid-sparing Remission With Rituximab

Abstract Introduction Diffuse alveolar hemorrhage (DAH) is a rare but life-threatening manifestation of antiphospholipid antibody syndrome (APS), occurring in < 1% of patients. It reflects antibody-mediated microvascular injury within the lung microenvironment, often manifesting as pulmonary capillaritis. The 2019 Current Rheumatology Reports review noted that among them, capillaritis is observed in only ∼30-50% of biopsies, and that remission is most effectively achieved with rituximab or cyclophosphamide (∼50%). We report a rare case of biopsy-proven APS-associated pulmonary capillaritis causing DAH, successfully treated with B-cell depletion therapy leading to sustained, steroid-sparing remission. Case Presentation A 45-year-old woman with APS (history of DVT, Budd-Chiari syndrome, portal vein thrombosis s/p venoplasty, on warfarin), SLE, IgA nephropathy, and prior heparin-induced thrombocytopenia presented with progressive cough and hypoxemia. CT chest showed bilateral patchy opacities unresponsive to antibiotics. Right-sided VATS wedge biopsy revealed diffuse intra-alveolar hemorrhage with neutrophilic capillaritis and hemosiderin-laden macrophages, consistent with APS-associated pulmonary capillaritis. Serology demonstrated positive ANA and p-ANCA (MPO-negative), but the histopathologic pattern and clinical context supported APS as the primary etiology of the pulmonary vasculitis. She received pulse-dose methylprednisolone followed by rituximab (1 g × 2 doses, 2 weeks apart) and a prednisone taper. Her course was complicated by COVID-19 pneumonia, treated with remdesivir, after which rituximab was resumed. She remains clinically stable on 15 mg prednisone, with no recurrent hemoptysis and improved functional status. Discussion This case underscores APS-associated pulmonary capillaritis as a distinct cause of DAH, independent of concomitant autoimmune disease. Lung biopsy confirmed immune-mediated endothelial injury without thrombosis, consistent with antiphospholipid antibody-driven capillaritis. The patient’s course reflects autoantibody-mediated endothelial damage and complement activation, disrupting the alveolar-capillary microenvironment and leading to intra-alveolar bleeding. Rituximab achieved durable, steroid-sparing remission, aligning with published response rates and reinforcing its role as targeted immunotherapy in refractory APS-DAH. Conclusion Biopsy confirmation established APS-associated pulmonary capillaritis as the cause of DAH, guiding the use of B-cell-directed immunotherapy. Rituximab achieved long-term remission and corticosteroid tapering, emphasizing the importance of early tissue diagnosis and targeted therapy in antibody-mediated pulmonary vascular injury. This abstract is funded by: None

Open article ↗



proteins
2026-09-29 | Interleukin-2 treatment ameliorates murine lupus diffuse alveolar hemorrhage with improvement in T cell subset imbalance

Abstract Objective This study evaluated the therapeutic efficacy and mechanism of interleukin-2 (IL-2) in a pristane-induced murine model of lupus-associated diffuse alveolar hemorrhage (DAH). Methods C57BL/6J mice received intraperitoneal pristane injection to induce lupus-like DAH. IL-2 was administered at varying doses. Disease severity, histopathological alterations, inflammatory infiltration, cytokine profiles, T cell subsets, and apoptosis were assessed using hematoxylin and eosin staining, immunohistochemistry, flow cytometry, ELISA, and TUNEL assays. Transcriptomic sequencing of lung tissue was performed to identify IL-2 treatment related molecular pathways. Results IL-2 treatment reduced the incidence and severity of DAH in a dose-dependent manner, with the 100,000 U dose achieving the best therapeutic effect. Treated mice exhibited improved weight maintenance, reduced lung weight, enhanced survival, ameliorated histopathological damage in the lungs with decreased pulmonary infiltration of F4/80+ macrophages and lowered levels of TNF-α, IL-6, IL-10, MIP-1, and SDF-1 in bronchoalveolar lavage fluid and peripheral blood. IL-2 treatment also increased CD4+ regulatory T cells, reduced effector T cells, improved the Treg/conventional T cells (Tcon) ratio, and corrected Th1/Th2 imbalance. Pulmonary apoptotic cell accumulation was also reduced. Transcriptomic analysis revealed that the IL-2 therapy corrected widespread gene expression abnormalities, suppressing pathways associated with inflammation, chemotaxis, adhesion, and innate immunity, while downregulating IL-6, TNF, IL-1, and Toll-like receptor signaling. Conclusion IL-2 treatment improved murine lupus-associated DAH by restoring T cell homeostasis, suppressing inflammatory cascades, and regulating apoptosis and transcriptomic networks. These findings underscore the potential of IL-2 as a therapeutic candidate for SLE-related DAH and provide novel mechanistic insights for translation.

Open article ↗



2026-06-08 | The Role of Macrophage M1/M2 Polarization Imbalance in the Pathogenesis of Immune Associated Diffuse Alveolar Hemorrhage: Evidence From the Study of Human Clinical Specimens.

An imbalance in M1/M2 macrophage polarization has been shown to play a critical role in the pathogenesis of diffuse alveolar hemorrhage (DAH) in mouse models. However, its contribution to immune-associated DAH in humans remains unclear. This study aimed to investigate the role of macrophage M1/M2 polarization imbalance in the pathogenesis of immune-associated DAH in children. A total of 24 children with immune-associated DAH (DAH group) and 13 children with acute airway foreign body or mild benign airway stenosis (control group) were enrolled. Bronchoalveolar lavage fluid (BALF) was obtained via bronchoscopy, and supernatant was isolated by centrifugation. Cytokine levels in BALF supernatant were measured using a cytometric bead array. Monocyte-derived macrophages (MDMs) were stimulated in vitro with BALF supernatant. The mRNA expression levels of M1 markers (IL-1β, TNF-α, IL-6, TGM2) and M2 markers (CD163, MRC1) were quantified using real-time PCR. Protein expression of surface markers (CD14, CD80, CD86, CD163, CD206) was analyzed by flow cytometry. (1) Levels of MCP-1, IL-6 and IL-8 in BALF supernatant were significantly higher in the DAH group than those in the control group. (2) MDMs stimulated with BALF supernatant from the DAH group showed significantly elevated mRNA expression of IL-1β and IL-6 and significantly reduced expression of MRC1 compared to those stimulated with control supernatant. (3) Flow cytometry revealed significantly higher CD86 expression and significantly lower CD163 and CD206 expression in MDMs treated with DAH group BALF supernatant. This study provides evidence that macrophage M1/M2 polarization imbalance contributes to the pathogenesis of immune-associated DAH in humans, highlighting a potential target for immunomodulatory therapy.

Open article ↗



2026-02-02 | Liraglutide prevents lupus-associated diffuse alveolar hemorrhage via inhibiting lymphocyte infiltration and promoting macrophage M2 polarization.

This study aimed to explore the prophylactic and therapeutic role of liraglutide for lupus-associated diffuse alveolar hemorrhage (DAH). A lupus-associated DAH model was established in 6-8-week-old female C57BL/6 mice via intraperitoneal injection of 0.5 mL pristane. Mice were randomized to receive daily intraperitoneal injections of either saline or liraglutide (2 mg/kg/day), starting either 14 days before or on the day of pristane injection, and continuing until 14 days post-injection. Body weight and blood glucose were monitored. Serum levels of anti-dsDNA, ANA, total IgM and IgG were quantified using ELISA. Lung tissues were collected for histopathological analysis with H&E and Prussian blue staining, respectively, characterization of different types of immune cells infiltration with flow cytometry (t-SNE for subset dimensionality reduction) and immunofluorescence, and quantification of protein levels with Western blot. Liraglutide significantly alleviated pulmonary hemorrhage, as evidenced by reduced lung wet weight, incidence of lung hemorrhage, pulmonary hemosiderin-laden macrophages, and total serum IgG, without affecting body weight or glucose. Mechanistically, liraglutide treatment reduced pulmonary infiltration of multiple T and B lymphocyte subsets (e.g., CD4+, CD8+, B220+), while concurrently increasing alveolar macrophages and promoting M2 macrophage polarization. The phenotypic shift was demonstrated by increased M2 cell numbers, elevated CD206 expression, and downregulation of M1 marker CD86 and upregulation of M2 marker CD163 as confirmed at the protein level. Liraglutide treatment effectively ameliorates lupus-associated DAH, potentially through modulation of T cells, B cells, and macrophages polarization, offering a novel prophylactic and therapeutic strategy for this fatal complication of lupus.

Open article ↗



2025-09-30 | Diffuse alveolar hemorrhage in a child with mild hemophilia A who underwent bone marrow transplantation for thalassemia: a case report

Diffuse alveolar hemorrhage (DAH) is a relatively rare complication of bone marrow transplantation (BMT) associated with a high risk of mortality. It generally occurs in the early post-transplant phase during severe thrombocytopenia; however, since most thrombocytopenic cases do not develop DAH, cofactors are at play. Here, we discuss the case of a 4-year-old male child with mild asymptomatic hemophilia A discovered on routine evaluation pre-BMT, who developed DAH after a fully matched sibling BMT for HbE/Beta-thalassemia. The patient presented on day +21 post-BMT with sudden onset of cough followed one day later by hemoptysis. He had received FVIII supplementation with PTT normalization and FVIII levels of 28%. A chest CT scan showed interstitial lung disease with areas of ground glass bilaterally, mainly in the lower lobes. A radiological diagnosis of DAH was made, and the child was treated with additional FVIII concentrate (Advate), blow-by oxygen supplementation, red blood cells transfusion, platelet transfusion, methylprednisolone, tranexamic acid, and antioxidants (vitamin C and E). He responded well and recovered in a few days. Mild hemophilia associated with DAH post-BMT has never been reported before, however, it should be considered as a potentially treatable cause of DAH after BMT. FVIII levels should be part of the routine workup of children developing DAH post-transplantation. In the presence of thrombocytopenia, high FVIII levels of >30-40% might be required to prevent/treat DAH.

Open article ↗



2025-09-28 | Management and outcome of immune-mediated diffuse alveolar hemorrhage: a single centre case series

The standard treatment of immune-mediated diffuse alveolar hemorrhage (IM-DAH) encompasses immunosuppression with glucocorticoids (GC) and either cyclophosphamide (CYC) or rituximab (RTX). The role of intravenous immunoglobulin (IVIg) and plasma exchange (PLEX) remains controversial. We conducted a single-centre retrospective observational study on patients admitted with IM-DAH to evaluate treatment approaches and outcomes. Twelve episodes were identified in ten patients. All episodes were treated with GC and nine with CYC. IVIg was administered as first-line and/or bridging therapy in three cases with concomitant infections or high infection risk. PLEX was used in six episodes. IVIg and PLEX were primarily used as add-on therapies or when other immunosuppression was not recommended. After one year, nine patients survived. The combination of GC and CYC was the most common treatment regimen. While the role of PLEX and IVIg is not well established, they may be beneficial as second-line or as add-on therapies in selected cases.

Open article ↗



cell therapies
2024-11-19 | Trained mesenchymal stromal cell-based therapy HXB-319 for treating diffuse alveolar hemorrhage in a pristane-induced murine model.

Mesenchymal stromal cells (MSCs) can modulate immune responses and suppress inflammation in autoimmune diseases. Although their safety has been established in clinical trials, the efficacy of MSCs is inconsistent due to variability in potency among different preparations and limited specificity in targeting mechanisms driving autoimmune diseases. We utilized high-dimensional design of experiments methodology to identify factor combinations that modulate gene expression by MSCs to mitigate inflammation. This led to a novel MSC-based cell therapy, HXB-319. Its anti-inflammatory properties were validated in vitro by flow cytometry, RT-PCR, and mass spectrophotometry. To evaluate in vivo efficacy, we treated a diffuse alveolar hemorrhage (DAH) mouse model (C57Bl/6). Seven days post-DAH induction with pristane, mice received either MSCs or HXB-319 (2X106 cells, IP). On day 14, peritoneal lavage fluid (PLF) and lung tissue were collected for flow cytometry, histopathological examination, and mRNA. HXB-319 increased gene expression levels of anti-inflammatory, angiogenic, and anti-fibrotic factors (eg, TSG-6, VEGF, and HGF). KEGG pathway analysis confirmed significant activation of relevant anti-inflammatory, angiogenic, and anti-fibrotic proteins, corroborating RT-PCR results. In the DAH model, HXB-319 significantly reduced lung inflammation and alveolar hemorrhage compared to MSC-treated and untreated DAH mice. HXB-319 treatment also significantly decreased neutrophils, plasmacytoid dendritic cells, and RORγT cells, increased FoxP3+ cells in PLF, and reversed alterations in mRNA encoding IL-6, IL-10, and TSG-6 in lung tissue compared to DAH mice. HXB-319 effectively controls inflammation and prevents tissue damage in pristine-induced DAH, highlighting its therapeutic potential for autoimmune inflammatory diseases.

Open article ↗



2024-01-30 | The anti-inflammatory effects of mesenchymal stem cells attenuate diffuse pulmonary hemorrhage.

There are few effective treatment options for diffuse pulmonary hemorrhage (DPH). We aimed to elucidate the therapeutic role and underlying mechanisms of mesenchymal stem cells (MSCs) and MSC-derived extracellular vesicles (MSC-EVs) in DPH. Therapeutic effects of MSCs/MSC-EVs in pristane-induced DPH mice were evaluated via pulmonary function testing and histopathology. Transcriptome sequencing analyzed differentially expressed genes in control, DPH, and MSC groups. The proportion of macrophage polarization was evaluated in vivo and in vitro via fluorescence-activated cell sorting in control, DPH, MSC, MSC-EV inhalation, and MSC-EV intravenous groups. Intraperitoneal injection of pristane induced diffuse alveolar hemorrhage, early fibrosis, and inflammation in C57BL/6 mice. Monocytes were depleted in the peripheral blood in DPH mice and MSCs were recruited to the lungs, resulting in significantly attenuated diffuse alveolar hemorrhage and suppressed immunological response. This was more effective in the hyperacute hemorrhage phase than the early inflammatory phase. An MSC treatment-mediated anti-inflammatory effect was observed in DPH mice. Furthermore, MSC-EVs inhalation or tail-vein injection could effectively reduce DPH injury. MSCs could suppress macrophage M1 polarization in DPH in vivo and in vitro. MSCs displayed significant therapeutic effects in pristane-induced DPH, which may be a promising cell-free therapeutic approach.

Open article ↗



2023-01-24 | Updates in idiopathic pulmonary hemosiderosis in 2022: A state of the art review.

This manuscript reports the recent advances in idiopathic pulmonary hemosiderosis (IPH), a rare cause of diffuse alveolar hemorrhage in children and adults. This narrative review of the literature summarizes different aspects of IPH, including proposed pathogenesis, patient demographics, clinical and radiological characteristics, treatment, and prognosis. Additionally, the association between Celiac Disease (CD) and IPH is carefully evaluated. IPH is a frequently misdiagnosed disease. The delay in the diagnosis of IPH is often significant but fortunately, appears to have decreased in recent years. IPH in adults and children have distinct demographic preferences. The autoantibodies are common in IPH but with a definite difference between the adult and pediatric populations. The definitive diagnosis of IPH requires lung biopsy and careful exclusion of all competing diagnoses, even with lung biopsy showing bland pulmonary hemorrhage. The presence of nonspecific inflammatory cells or lymphoid aggregates may suggest a secondary immunologic phenomenon and needs careful evaluation and follow-up. A substantial number of patients suffer from coexisting CD, also known as Lane-Hamilton syndrome (LHS), and all patients with IPH need to be evaluated for LHS by serology. Although strict gluten free diet can manage the majority of patients with LHS, other patients generally require immunosuppressive therapy. The corticosteroids are the backbone of IPH therapy. Recently utilized experimental treatment options include mesenchymal stem cell transplant, liposteroid and bronchial artery embolization. The immunosuppression should be adjusted to achieve optimal disease control. Patients may progress to end-stage lung disease despite all measures, and lung transplantation may be the only viable option.

Open article ↗



2022-10-04 | Exosomes Derived from Human Umbilical Cord Mesenchymal Stem Cells Alleviate Diffuse Alveolar Hemorrhage Associated with Systemic Lupus Erythematosus in Mice by Promoting M2 Macrophage Polarization via the microRNA-146a-5p/NOTCH1 Axis.

Systemic lupus erythematosus (SLE)-associated diffuse alveolar hemorrhage (DAH) is a rare but extremely harmful condition. The current study sought to dissect the mechanisms underlying the effects of human umbilical cord mesenchymal stem cell (HUCMSC)-derived exosomes on M2 macrophage polarization in SLE-associated DAH via the microRNA (miR)-146a-5p/NOTCH1 axis. A DAH mouse model was established using pristane. Exosomes were isolated from HUCMSCs transfected or untransfected with the miR-146a-5p antagonist or agonist and their NCs and then injected into DAH mice. Additionally, miR-146a-5p was overexpressed in macrophages. Expression of miR-146a-5p, NOTCH1, M1 macrophage markers, and M2 macrophage markers was measured in mice and macrophages, and inflammatory factor levels were detected. Mouse lung injuries were evaluated, so was the binding of miR-146a-5p to NOTCH1. Rescue experiments were conducted in mice and macrophages using NOTCH1 shRNA and pcDNA3.1-NOTCH1, respectively. NOTCH1 expression was enhanced in DAH mice. HUCMSC-derived exosomes reduced NOTCH1 expression, bleeding, inflammation, and M1 macrophage polarization but elevated M2 macrophage polarization in lung tissues of DAH mice. Mechanistically, NOTCH1 is negatively targeted by miR-146a-5p. miR-146a-5p overexpression diminished M1 marker and inflammatory factor levels but enhanced M2 marker levels in macrophages, which was nullified by NOTCH1 overexpression. HUCMSC-derived exosomes with miR-146a-5p inhibition increased NOTCH1 expression, worsened bleeding and inflammation, and augmented M1 macrophage polarization while decreasing M2 macrophage polarization in lung tissues of DAH mice, which was abrogated by silencing NOTCH1. HUCMSC-derived exosomes diminished NOTCH1 expression to accelerate M2 macrophage polarization via delivery of miR-146a-5p, thus alleviating SLE-associated DAH in mice.

Open article ↗



2012-08-21 | Allogeneic transplantation of umbilical cord-derived mesenchymal stem cells for diffuse alveolar hemorrhage in systemic lupus erythematosus.

Umbilical cord-derived mesenchymal stem cell transplantation (UC-MSCT) has been proved to be effective in the treatment of systemic lupus erythematosus (SLE), based on animal experiments and clinical trials. Diffuse alveolar hemorrhage (DAH) is a rare complication of SLE with a high mortality usually over 50%. This study aimed to assess the efficacy of UC-MSCT in the treatment of SLE-associated DAH. Four SLE patients complicated with DAH, who underwent UC-MSCT, were included. Clinical changes before and after transplantation were assessed by measurements of hemoglobin, platelet level, oxygen saturation, and serological factors. High-resolution CT (HRCT) scans of the chest were performed to evaluate pulmonary manifestation. All the four patients showed dramatic improvements of their clinical manifestations. Hemoglobin was elevated after UC-MSCT and was sustained at a normal level 6 months after UC-MSCT in the four patients. Platelet level was upregulated in two patients who had thrombocytopenia at baseline. Oxygen saturation appeared to be normal at 1 month after UC-MSCT, and this result was confirmed by the HRCT scan of the chest. Serum albumin elevated to 3.5 g/dl 6 months after transplantation. Our findings suggest that UC-MSCT results in amelioration of oxygen saturation as well as hematological and serologic changes, which revealed that UC-MSCT could be applied as a salvage strategy for DAH patients.

Open article ↗



other
2022-08-26 | Down-regulated miR-146a expression with increased neutrophil extracellular traps and apoptosis formation in autoimmune-mediated diffuse alveolar hemorrhage

Increasing evidences have suggested an important role of microRNAs (miRNAs) in regulating cell death processes including NETosis and apoptosis. Dysregulated expression of miRNAs and increased formation of neutrophil extracellular traps (NETs) and apoptosis participate in autoimmune-mediated diffuse alveolar hemorrhage (DAH), mostly associated with pulmonary capillaritis in systemic lupus erythematosus (SLE) patients. In particular, besides the inhibition of apoptosis, miR-146a can control innate and acquired immune responses, and regulate the toll-like receptor pathway through targeting TRAF6 to reduce the expression of pro-inflammatory cytokines/chemokines like IL-8, a NETosis inducer.Expression of miR-146a, TRAF6 and NETs were examined in peripheral blood neutrophils (PBNs) and lung tissues from SLE-associated DAH patients, and in neutrophils and pristane-induced DAH lung tissues from C57BL/6 mice. To assess NETs formation, we examined NETosis-related DNAs morphology and crucial mediators including protein arginine deiminase 4 and citrullinated Histone 3. Expression of miR-146a and its endogenous RNA SNHG16 were studied in HL-60 promyelocytic cells and MLE-12 alveolar cells during NETosis and apoptosis processes, respectively. MiR-146a-overexpressed and CRISPR-Cas13d-mediated SNHG16-silenced HL-60 cells were investigated for NETosis. MiR-146a-overexpressed MLE-12 cells were analyzed for apoptosis. Pristane-injected mice received intra-pulmonary miR-146a delivery to evaluate therapeutic efficacy in DAH.In DAH patients, there were down-regulated miR-146a levels with increased TRAF6 expression and PMA/LPS-induced NETosis in PBNs, and down-regulated miR-146a levels with increased TRAF6, high-mobility group box 1 (HMGB1), IL-8, NETs and apoptosis expression in lung tissues. HMGB1-stimulated mouse neutrophils had down-regulated miR-146a levels with increased TRAF6, IL-8 and NETs expression. PMA-stimulated HL-60 cells had down-regulated miR-146a levels with enhanced NETosis. MiR-146a-overexpressed or SNHG16-silenced HL-60 cells showed reduced NETosis. Apoptotic MLE-12 cells had down-regulated miR-146a expression and increased HMGB1 release, while miR-146a-overexpressed MLE-12 cells showed reduced apoptosis and HMGB1 production. There were down-regulated miR-146a levels with increased TRAF6, HMGB1, IL-8, NETs and apoptosis expression in mouse DAH lung tissues. Intra-pulmonary miR-146a delivery could suppress DAH by reducing TRAF6, IL-8, NETs and apoptosis expression.Our results demonstrate firstly down-regulated pulmonary miR-146a levels with increased TRAF6 and IL-8 expression and NETs and apoptosis formation in autoimmune-mediated DAH, and implicate a therapeutic potential of intra-pulmonary miR-146a delivery.

Open article ↗



2021-06-28 | Targeting Intra-Pulmonary P53-Dependent Long Non-Coding RNA Expression as a Therapeutic Intervention for Systemic Lupus Erythematosus-Associated Diffuse Alveolar Hemorrhage

Diffuse alveolar hemorrhage (DAH) in systemic lupus erythematosus (SLE) is associated with significant mortality, requiring a thorough understanding of its complex mechanisms to develop novel therapeutics for disease control. Activated p53-dependent apoptosis with dysregulated long non-coding RNA (lncRNA) expression is involved in the SLE pathogenesis and correlated with clinical activity. We examined the expression of apoptosis-related p53-dependent lncRNA, including H19, HOTAIR and lincRNA-p21 in SLE-associated DAH patients. Increased lincRNA-p21 levels were detected in circulating mononuclear cells, mainly in CD4+ and CD14+ cells. Higher expression of p53, lincRNA-p21 and cell apoptosis was identified in lung tissues. Lentivirus-based short hairpin RNA (shRNA)-transduced stable transfectants were created for examining the targeting efficacy in lncRNA. Under pristane stimulation, alveolar epithelial cells had increased p53, lincRNA-p21 and downstream Bax levels with elevated apoptotic ratios. After pristane injection, C57/BL6 mice developed DAH with increased pulmonary expression of p53, lincRNA-p21 and cell apoptosis. Intra-pulmonary delivery of shRNA targeting lincRNA-p21 reduced hemorrhage frequencies and improved anemia status through decreasing Bax expression and cell apoptosis. Our findings demonstrate increased p53-dependent lncRNA expression with accelerated cell apoptosis in the lungs of SLE-associated DAH patients, and show the therapeutic potential of targeting intra-pulmonary lncRNA expression in a pristane-induced model of DAH.

Open article ↗



2016-03-28 | In Vivo Therapeutic Success of MicroRNA‐155 Antagomir in a Mouse Model of Lupus Alveolar Hemorrhage

Objective Diffuse alveolar hemorrhage (DAH) is a rare but life‐threatening complication of systemic lupus erythematosus (SLE). Pristane‐treated B6 mice develop severe DAH within 2 weeks of treatment. MicroRNA‐155 (miR‐155) is a pleiotropic microRNA that plays a crucial role in the regulation of immune responses. Recent studies have revealed a pathogenic role of miR‐155 in various autoimmune disorders. The purpose of this study was to examine the role of miR‐155 in the development of DAH in pristane‐induced lupus using miR‐155–knockout (miR‐155 −/− ) mice and miR‐155 antagomir to silence miR‐155. Methods DAH was induced by an intraperitoneal injection of 0.5 ml of pristane. MicroRNA‐155 antagomir was administered intravenously to silence miR‐155 expression. Lung tissues were collected for RNA extraction and were embedded in paraffin for sectioning. Gene expression profiling data were analyzed using Ingenuity Pathway Analysis. Real‐time quantitative polymerase chain reaction analysis was used for single‐gene validation. Luciferase reporter assay and argonaute 2 immunoprecipitation were performed for target validation. Results MicroRNA‐155 expression was significantly increased during the development of DAH. Disease progression was reduced in miR‐155 −/− mice as well as by in vivo silencing of miR‐155 using a miR‐155 antagomir. MicroRNA‐155 silencing dampened pristane‐induced ectopic activation of multiple inflammatory pathways and reduced the expression of proinflammatory cytokines. Several negative regulators of NF‐κB signaling were inhibited by pristane and were reactivated in miR‐155 −/− mice. In particular, the antiinflammatory factor peroxisome proliferator–activated receptor α was identified as a direct target of miR‐155. Conclusion MicroRNA‐155 promotes pristane‐induced lung inflammation. It contributes to ectopic activation of NF‐κB signaling pathways by targeting multiple negative regulators. MicroRNA‐155 antagomir may be a promising therapeutic strategy for treating acute lung inflammation in lupus.

Open article ↗



2008-10-01 | A NOVEL TREATMENT FOR RECURRENT DIFFUSE ALVEOLAR HEMORRHAGE ASSOCIATED WITH NON-MYELOABLATIVE ALLOGENIC STEM CELL TRANSPLANTATION

INTRODUCTION: Diffuse alveolar hemorrhage (DAH) occurs in about 5% of hematopoietic stem cell transplant (HSCT) recipients with a mortality rate of 30 – 70% (1Afessa B Tefferi A Litzow MR et al.Diffuse alveolar hemorrhage in hematopoietic stem cell transplant recipients.Am J Respir Crit Care Med. 2002; 166: 641-645Crossref PubMed Scopus (153) Google Scholar). We describe a patient with recurrent episodes of DAH occurring late in the post-HSCT course.

Open article ↗



small molecules
2026-09-17 | Hydrocephalus and Diffuse Alveolar Hemorrhage as the Initial Manifestation of Systemic Lupus Erythematosus and Antiphospholipid Syndrome: A Case Report.

Systemic lupus erythematosus (SLE) is an autoimmune disease that can affect many systems, such as the central nervous system (CNS), cardiovascular, musculocutaneous, renal, and respiratory systems, etc. SLE can occur alone or in association with other autoimmune diseases, especially antiphospholipid syndrome (APS). Hydrocephalus and diffuse alveolar hemorrhage (DAH) are infrequent manifestations of SLE and APS and increase the risk of mortality and morbidity in these patients. A 48-year-old man was hospitalized due to fever, hemoptysis, and headache, which had not been examined for diagnosis and treatment for a long period of time because of his negligence. After imaging and autoimmune tests were performed, hydrocephalus and DAH were diagnosed as initial manifestations of SLE in association with APS according to the SLE/APS criteria. Additionally, lupus nephritis was confirmed via renal biopsy. The hydrocephalus was due to sigmoid sinus thrombosis in the context of a hypercoagulable state of SLE and APS. The initiation of steroid and immunosuppressive treatments has yielded positive results, negating the need for any invasive procedures. The coexistence of SLE and hydrocephalus, although uncommon, has been documented in the literature. Hydrocephalus, a rare complication of SLE, necessitates timely decision-making regarding treatment based on the patient's clinical symptoms and the degree of ventricular dilation, which may involve either conservative medical management or surgical procedures such as a VP shunt. In patients with multiorgan involvement, rheumatological and autoimmune diseases are among our most important differential diagnoses. Importantly, neurological symptoms, particularly headaches, should not be underestimated, even though they are commonly observed in patients with SLE or APS. A detailed medical history, a comprehensive examination, and strong clinical suspicion are essential when patients present with neurological symptoms, and physicians must consider autoimmune diseases in their differential diagnoses.

Open article ↗



2026-09-08 | Diffuse Alveolar Hemorrhage: A Rare and Life-Threatening Manifestation of Fat Embolism Syndrome

Fat embolism syndrome (FES) often occurs following a long bone fracture and typically manifests within 24–72 h as respiratory distress, petechiae, and neurological signs. Fat embolism associated diffuse alveolar hemorrhage (DAH) is a rare but potentially life-threatening pulmonary complication. Here, we present a case of a 22-year-old male with femur and mandibular fractures following trauma who developed progressive hypoxemia and hemoptysis on day 2 of trauma. Chest X-ray imaging revealed bilateral alveolar infiltrates, and bronchoscopy confirmed alveolar hemorrhage. The patient was placed on mechanical ventilation due to severe alveolar hemorrhage. Treatment was initiated with methylprednisolone, along with nebulization of adrenaline and tranexamic acid to control the bleeding. DAH secondary to FES should be suspected in trauma patients presenting with hemoptysis and hypoxemia. Early diagnosis and prompt administration of corticosteroids and antifibrinolytic therapy can significantly improve patient outcomes.

Open article ↗



2026-09-03 | Androgen-associated remodeling of pulmonary NK cells and sex-biased susceptibility in lupus-associated diffuse alveolar hemorrhage.

Diffuse alveolar hemorrhage (DAH) is a lethal, female-biased complication of systemic lupus erythematosus (SLE). While adaptive immunity is a known driver, the role of innate lymphoid cells (ILCs) in DAH and the contribution of sex hormones to this process remain unclear. To characterize pulmonary ILC remodeling during DAH and evaluate whether androgen signaling modulates natural killer (NK) cell homeostasis and disease severity. A pristane-induced DAH model was established in C57BL/6J and Rag2 -/- mice. Pulmonary ILCs were profiled by single-cell transcriptomics and flow cytometry. Baseline sex differences were compared between healthy humans and mice. In vivo interventions included male castration, female testosterone propionate (TP) administration, and antibody-mediated NK cell depletion. DAH was accompanied by a marked reduction in pulmonary NK cell frequency in both C57BL/6J and Rag2 -/- mice, indicating an innate feature independent of adaptive lymphocytes. DAH-associated NK cells displayed an activated but constrained state, showing increased expression of effector-associated genes Prf1 and Ifng, together with the inhibitory receptor gene Lag3. At baseline, healthy human females and female mice exhibited lower NK cell frequencies than males. While male castration did not significantly alter DAH severity, TP administration in females restored pulmonary NK cell dominance and significantly attenuated disease severity. NK cell depletion prior to challenge led to a trend toward more severe hemorrhage (p = 0.084). Pulmonary NK cells are reduced in a lupus-associated DAH model and may participate in disease development. Androgen treatment restores pulmonary NK cell predominance and attenuates DAH severity, supporting further investigation of strategies aimed at restoring or preserving pulmonary NK cell homeostasis and function as potential therapeutic approaches for DAH.

Open article ↗



2026-08-12 | Diffuse Alveolar Hemorrhage Following Trauma: A Diagnostic Dilemma With Rapid Steroid Response.

Diffuse alveolar hemorrhage (DAH) is a rare but potentially life-threatening pulmonary condition that, while classically linked to autoimmune disorders, can occur in the setting of trauma. We report the case of a 20-year-old male who sustained polytrauma following a road traffic accident and initially had a normal chest radiograph. On the fourth day of hospitalization, he developed acute hypoxemia with new bilateral alveolar infiltrates; high-resolution computed tomography revealed diffuse ground-glass opacities with septal thickening. Bronchoalveolar lavage demonstrated progressively hemorrhagic return across aliquots, confirming DAH. Autoimmune markers were largely negative, and in the absence of systemic features, a multifactorial etiology involving trauma-related injury and anticoagulant use was considered. High-dose intravenous corticosteroids produced rapid clinical and radiological recovery. This case underscores the importance of considering DAH in trauma patients presenting with unexplained hypoxemia and bilateral infiltrates, even without hemoptysis, where early bronchoscopy and prompt treatment can be lifesaving.

Open article ↗



2026-08-01 | Diffuse alveolar hemorrhage in ANCA-associated vasculitis: Current evidence and multimodal treatment approaches.

Diffuse alveolar hemorrhage (DAH) is a rare but life-threatening complication of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV), with management largely extrapolated from broader AAV and ARDS literature. We conducted a review of studies published between 2000 and 2025 evaluating treatments and outcomes in AAV-associated DAH, synthesizing evidence across immunosuppressive, plasmapheresis, hemostatic, respiratory and hemodynamic, and infection prevention strategies. Glucocorticoids combined with rituximab or cyclophosphamide induce remission in most patients, although optimal steroid tapering and comparative efficacy in severe, ventilated DAH remain uncertain. Avacopan improves sustained remission and renal recovery in severe AAV and appears to be a feasible steroid-sparing adjunct in early DAH series. Large randomized trials demonstrate no survival benefit of plasma exchange. Local hemostatic therapies may provide rapid bleeding control, but evidence is limited. Respiratory outcomes are driven by hypoxemia severity and need for invasive ventilation or extracorporeal support. Lastly, infection prevention measures are strongly supported.

Open article ↗



antibodies
2026-06-30 | Unilateral diffuse alveolar haemorrhage as an atypical presentation of PR3-ANCA-associated vasculitis: A case report.

Diffuse alveolar haemorrhage (DAH) is a life-threatening pulmonary manifestation of small-vessel vasculitis, most commonly associated with anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis. Unilateral DAH has been infrequently reported and may pose diagnostic challenges, as its radiological presentation can mimic pneumonia, pulmonary oedema, or localized haemorrhage. This atypical presentation may delay recognition of the underlying vasculitis and appropriate immunosuppressive therapy. We present a case of a woman in her thirties with previously diagnosed PR3-ANCA-associated vasculitis who presented with acute worsening of dyspnea (mMRC grade IV) and hemoptysis. Radiological assessments revealed extensive right-sided ground-glass opacities with areas of consolidation and minimal left lower lobe involvement. Bronchoscopy with sequential bronchoalveolar lavage (BAL) showed progressively haemorrhagic aliquots consistent with DAH. Laboratory investigations revealed anemia (Hb 7.1 mg/dL) and elevated serum creatinine (5.02 mg/dL). The patient developed type I respiratory failure requiring mechanical ventilation and hemodialysis. She was treated with pulse intravenous methylprednisolone followed by rituximab therapy, along with trimethoprim-sulfamethoxazole prophylaxis. The patient improved clinically, radiologically, and biochemically and was discharged on supplemental oxygen.

Open article ↗



2026-05-29 | Alveolar dysregulation of host response in pneumonia and ARDS: implications for immune modulation and infection.

Respiratory failure due to pneumonia and acute respiratory distress syndrome (ARDS) remains a major cause of morbidity and mortality in the intensive care unit. The alveolar compartment plays a central role in both pathogen clearance and tissue injury, yet its biology is poorly captured by systemic measurements. Growing evidence shows that dysregulation of alveolar host responses drives disease progression, shapes susceptibility to secondary infections, and influences recovery. Community-, hospital-, and ventilator-associated pneumonia differ in microbial drivers and host responses, but all share a pattern of localized inflammation. In most cases, pathogens are rapidly controlled following antimicrobial treatment, while alveolar inflammation persists. This persistence likely reflects self-reinforcing cycles between epithelial injury, neutrophil activity, and monocyte-macrophage dysfunction. Mechanical ventilation further disrupts local defenses, promoting microbial overgrowth and ventilator-associated pneumonia.In ARDS, diffuse alveolar damage initiates an early influx of neutrophils and monocyte-derived macrophages. Although peripheral blood has been used to identify systemic inflammatory subphenotypes, molecular signatures in the alveolar compartment often differ and may provide complementary biological information. Patients may diverge into distinct alveolar immune trajectories, ranging from sustained alveolar hyperinflammation to immune exhaustion. These divergent trajectories influence downstream repair, determining whether patients achieve epithelial recovery or develop fibrotic remodeling.Alveolar immune dysregulation also creates a permissive niche for viral and fungal pathogens. Pulmonary reactivation of herpes simplex virus or cytomegalovirus and fungal infections with Aspergillus frequently occur in critically ill patients and may reflect impaired local host defense. These processes are associated with prolonged mechanical ventilation and illustrate how impaired alveolar defenses may sustain injury and propagate complications. Pneumonia and ARDS share common pathways of alveolar immune dysregulation that are not adequately captured by systemic profiling alone. Integrating systemic and alveolar immune assessment, including their concordance and discordance, may improve patient stratification, facilitate identification of treatable traits, and support the development of more personalized, compartment-informed therapeutic strategies, including both immunomodulatory and pathogen-directed interventions. A more refined understanding of compartment-specific host responses will be key to advancing these approaches.

Open article ↗



2026-05-01 | A35-24 Coughing Up Clues: Diffuse Alveolar Hemorrhage Revealing a Hidden Vasculitis

Abstract Diffuse alveolar hemorrhage (DAH) is a condition characterized by widespread bleeding into the alveoli through disruption of the alveolar-capillary membrane. It usually presents with nonspecific symptoms such as cough, hemoptysis, and dyspnea. DAH is frequently associated with small-vessel vasculitides, such as microscopic polyangiitis (MPA). MPA is a systemic, necrotizing form of small-vessel vasculitis that causes endothelial inflammation and injury, particularly affecting the kidneys and respiratory tract. In MPA, decreased immune tolerance of myeloperoxidase (MPO) prompts the formation of myeloperoxidase-antineutrophil cytoplasmic antibodies (MPO-ANCA). In the setting of DAH, MPA leads to pulmonary capillaritis, necrosis of the alveolar septa causing structural degradation and hemorrhage. 25-year-old male presents to the ED with a 1-week history of hemoptysis and hematuria. Upon evaluation in the ED, patient was noted to be tachypneic and tachycardic requiring BiPAP for respiratory support. Initial workup was significant for AKI and acute anemia. Chest X-ray showed diffuse interstitial and alveolar opacities, initially thought to be infectious vs edematous in nature. Heparin was also briefly started for possible pulmonary embolism but was quickly discontinued following worsening anemia and hemoptysis. Bronchoscopy was performed in setting of worsening respiratory distress with bronchoalveolar lavage with grossly pure blood. Autoimmune panel was positive for rheumatoid factor and ANA. Given these results and presentation of hemoptysis with hematuria, nephrology was consulted for further evaluation of possible systemic vasculitis. Renal biopsy was performed which revealed crescentic glomerulonephritis with positive MPO antibodies concerning for a pauci-immune vasculitis consistent with microscopic polyangiitis. After establishing vasculitis as the underlying etiology, the patient was subsequently treated with high-dose methylprednisolone and rituximab infusions. Repeat imaging performed one month later demonstrated complete resolution of bilateral infiltrates.Diffuse alveolar hemorrhage (DAH) has a broad differential, including autoimmune, infectious, and drug-induced causes. Bronchoscopic or histological evaluation may be required to establish the underlying diagnosis. In cases of microscopic polyangiitis, DAH is often due to early pulmonary capillaritis. Initial chest imaging may mimic pneumonia, which can delay diagnosis. While uncommon, DAH due to vasculitis should remain on the differential in patients with hemoptysis and diffuse infiltrates, particularly when accompanied by renal dysfunction. First-line therapy for DAH due to MPA includes high-dose corticosteroids combined with immunosuppressive agents such as rituximab or cyclophosphamide. Prognosis of DAH varies widely and is closely tied to the underlying cause. In ANCA-associated vasculitis, 5-year all-cause mortality is estimated to approach 25 percent. This abstract is funded by: None

Open article ↗



2026-05-01 | A33-39 Breathing Blood in a Triple Threat: Pulmonary-Renal Catastrophe and Diffuse Alveolar Hemorrhage in Lupus Triggered by Covid-19

Abstract Introduction Pulmonary-renal syndrome (PRS) is one of the most catastrophic complications of systemic lupus erythematosus (SLE), driven by complement-mediated endothelial injury. Diffuse alveolar hemorrhage (DAH) is a life-threatening pulmonary emergency, with high mortality, characterized by bleeding into alveolar spaces from alveolar-capillary membrane disruption. DAH may be exacerbated by infections that trigger complement activation, particularly in underlying conditions such as SLE, atypical hemolytic uremic syndrome (aHUS), and thrombotic microangiopathy (TMA). We present the case of recurrent DAH secondary to complement-mediated aHUS flare triggered by coronavirus disease 2019 (COVID-19) in a patient with SLE, culminating in multi-organ failure, highlighting the challenges of managing overlapping immune dysregulation successfully treated with multimodal immunotherapy. Description A 31-year-old male with SLE complicated by Class IV lupus nephritis, TMA, and aHUS presented with acute fever, chills, and dyspnea. Upon arrival, he was in severe respiratory distress, hypoxemic (SpO2 70% on ambient air), febrile (101 °F), tachycardic (115 bpm), and hypotensive (83/61 mmHg). Point-of-care ultrasound revealed diffuse B-lines; chest radiograph showed right lower lung field haziness. Laboratory studies demonstrated acute kidney injury (creatinine 3.08 mg/dL), anemia (hemoglobin 11.8 g/dL), thrombocytopenia (platelets 72K/uL), and metabolic acidosis (pH 7.24, lactate 3.0 mmol/L). His respiratory status rapidly deteriorated requiring emergent intubation, complicated by a 4-minute pulseless electrical activity, with return of spontaneous circulation. In the intensive care unit, he developed multi-organ failure. Bronchoscopy with bronchoalveolar lavage confirmed DAH, consistent with prior episodes; this was attributed to PRS with an underlying aHUS flare exacerbating DAH. Infectious workup concurrently revealed COVID-19 pneumonia, E. coli bacteremia, and ESBL Klebsiella ventilator-associated pneumonia. He was treated with remdesivir and meropenem. Management of aHUS flare and PRS included aggressive immunomodulation: high-dose corticosteroids, plasma exchange, intravenous immunoglobulin, and eculizumab. Given history of refractory disease, additional immunosuppression with rituximab and cyclophosphamide were administered. He developed acute renal failure, requiring continuous renal replacement therapy for seven days, followed by complete renal and pulmonary recovery allowing successful extubation. Discussion What began as COVID-19 pneumonia unraveled into a deadly cascade of complement activation, endothelial injury, and diffuse hemorrhage, culminating in pulmonary-renal catastrophe. This case illustrates the challenges in managing DAH and PRS in patients with complement-mediated aHUS, where infection and immune overactivation coexist. While COVID-19 may have triggered the complement cascade, the key clinical challenge was balancing aggressive immunosuppression amid infection. Our patient’s successful recovery highlights the importance of multimodal immunotherapy and early recognition of complement dysregulation to prevent irreversible pulmonary-renal damage. This abstract is funded by: None

Open article ↗



2026-05-01 | B35-53 Antiphospholipid Syndrome-associated Pulmonary Capillaritis Causing Diffuse Alveolar Hemorrhage: Sustained Steroid-sparing Remission With Rituximab

Abstract Introduction Diffuse alveolar hemorrhage (DAH) is a rare but life-threatening manifestation of antiphospholipid antibody syndrome (APS), occurring in < 1% of patients. It reflects antibody-mediated microvascular injury within the lung microenvironment, often manifesting as pulmonary capillaritis. The 2019 Current Rheumatology Reports review noted that among them, capillaritis is observed in only ∼30-50% of biopsies, and that remission is most effectively achieved with rituximab or cyclophosphamide (∼50%). We report a rare case of biopsy-proven APS-associated pulmonary capillaritis causing DAH, successfully treated with B-cell depletion therapy leading to sustained, steroid-sparing remission. Case Presentation A 45-year-old woman with APS (history of DVT, Budd-Chiari syndrome, portal vein thrombosis s/p venoplasty, on warfarin), SLE, IgA nephropathy, and prior heparin-induced thrombocytopenia presented with progressive cough and hypoxemia. CT chest showed bilateral patchy opacities unresponsive to antibiotics. Right-sided VATS wedge biopsy revealed diffuse intra-alveolar hemorrhage with neutrophilic capillaritis and hemosiderin-laden macrophages, consistent with APS-associated pulmonary capillaritis. Serology demonstrated positive ANA and p-ANCA (MPO-negative), but the histopathologic pattern and clinical context supported APS as the primary etiology of the pulmonary vasculitis. She received pulse-dose methylprednisolone followed by rituximab (1 g × 2 doses, 2 weeks apart) and a prednisone taper. Her course was complicated by COVID-19 pneumonia, treated with remdesivir, after which rituximab was resumed. She remains clinically stable on 15 mg prednisone, with no recurrent hemoptysis and improved functional status. Discussion This case underscores APS-associated pulmonary capillaritis as a distinct cause of DAH, independent of concomitant autoimmune disease. Lung biopsy confirmed immune-mediated endothelial injury without thrombosis, consistent with antiphospholipid antibody-driven capillaritis. The patient’s course reflects autoantibody-mediated endothelial damage and complement activation, disrupting the alveolar-capillary microenvironment and leading to intra-alveolar bleeding. Rituximab achieved durable, steroid-sparing remission, aligning with published response rates and reinforcing its role as targeted immunotherapy in refractory APS-DAH. Conclusion Biopsy confirmation established APS-associated pulmonary capillaritis as the cause of DAH, guiding the use of B-cell-directed immunotherapy. Rituximab achieved long-term remission and corticosteroid tapering, emphasizing the importance of early tissue diagnosis and targeted therapy in antibody-mediated pulmonary vascular injury. This abstract is funded by: None

Open article ↗



proteins
2026-09-29 | Interleukin-2 treatment ameliorates murine lupus diffuse alveolar hemorrhage with improvement in T cell subset imbalance

Abstract Objective This study evaluated the therapeutic efficacy and mechanism of interleukin-2 (IL-2) in a pristane-induced murine model of lupus-associated diffuse alveolar hemorrhage (DAH). Methods C57BL/6J mice received intraperitoneal pristane injection to induce lupus-like DAH. IL-2 was administered at varying doses. Disease severity, histopathological alterations, inflammatory infiltration, cytokine profiles, T cell subsets, and apoptosis were assessed using hematoxylin and eosin staining, immunohistochemistry, flow cytometry, ELISA, and TUNEL assays. Transcriptomic sequencing of lung tissue was performed to identify IL-2 treatment related molecular pathways. Results IL-2 treatment reduced the incidence and severity of DAH in a dose-dependent manner, with the 100,000 U dose achieving the best therapeutic effect. Treated mice exhibited improved weight maintenance, reduced lung weight, enhanced survival, ameliorated histopathological damage in the lungs with decreased pulmonary infiltration of F4/80+ macrophages and lowered levels of TNF-α, IL-6, IL-10, MIP-1, and SDF-1 in bronchoalveolar lavage fluid and peripheral blood. IL-2 treatment also increased CD4+ regulatory T cells, reduced effector T cells, improved the Treg/conventional T cells (Tcon) ratio, and corrected Th1/Th2 imbalance. Pulmonary apoptotic cell accumulation was also reduced. Transcriptomic analysis revealed that the IL-2 therapy corrected widespread gene expression abnormalities, suppressing pathways associated with inflammation, chemotaxis, adhesion, and innate immunity, while downregulating IL-6, TNF, IL-1, and Toll-like receptor signaling. Conclusion IL-2 treatment improved murine lupus-associated DAH by restoring T cell homeostasis, suppressing inflammatory cascades, and regulating apoptosis and transcriptomic networks. These findings underscore the potential of IL-2 as a therapeutic candidate for SLE-related DAH and provide novel mechanistic insights for translation.

Open article ↗



2026-06-08 | The Role of Macrophage M1/M2 Polarization Imbalance in the Pathogenesis of Immune Associated Diffuse Alveolar Hemorrhage: Evidence From the Study of Human Clinical Specimens.

An imbalance in M1/M2 macrophage polarization has been shown to play a critical role in the pathogenesis of diffuse alveolar hemorrhage (DAH) in mouse models. However, its contribution to immune-associated DAH in humans remains unclear. This study aimed to investigate the role of macrophage M1/M2 polarization imbalance in the pathogenesis of immune-associated DAH in children. A total of 24 children with immune-associated DAH (DAH group) and 13 children with acute airway foreign body or mild benign airway stenosis (control group) were enrolled. Bronchoalveolar lavage fluid (BALF) was obtained via bronchoscopy, and supernatant was isolated by centrifugation. Cytokine levels in BALF supernatant were measured using a cytometric bead array. Monocyte-derived macrophages (MDMs) were stimulated in vitro with BALF supernatant. The mRNA expression levels of M1 markers (IL-1β, TNF-α, IL-6, TGM2) and M2 markers (CD163, MRC1) were quantified using real-time PCR. Protein expression of surface markers (CD14, CD80, CD86, CD163, CD206) was analyzed by flow cytometry. (1) Levels of MCP-1, IL-6 and IL-8 in BALF supernatant were significantly higher in the DAH group than those in the control group. (2) MDMs stimulated with BALF supernatant from the DAH group showed significantly elevated mRNA expression of IL-1β and IL-6 and significantly reduced expression of MRC1 compared to those stimulated with control supernatant. (3) Flow cytometry revealed significantly higher CD86 expression and significantly lower CD163 and CD206 expression in MDMs treated with DAH group BALF supernatant. This study provides evidence that macrophage M1/M2 polarization imbalance contributes to the pathogenesis of immune-associated DAH in humans, highlighting a potential target for immunomodulatory therapy.

Open article ↗



2026-02-02 | Liraglutide prevents lupus-associated diffuse alveolar hemorrhage via inhibiting lymphocyte infiltration and promoting macrophage M2 polarization.

This study aimed to explore the prophylactic and therapeutic role of liraglutide for lupus-associated diffuse alveolar hemorrhage (DAH). A lupus-associated DAH model was established in 6-8-week-old female C57BL/6 mice via intraperitoneal injection of 0.5 mL pristane. Mice were randomized to receive daily intraperitoneal injections of either saline or liraglutide (2 mg/kg/day), starting either 14 days before or on the day of pristane injection, and continuing until 14 days post-injection. Body weight and blood glucose were monitored. Serum levels of anti-dsDNA, ANA, total IgM and IgG were quantified using ELISA. Lung tissues were collected for histopathological analysis with H&E and Prussian blue staining, respectively, characterization of different types of immune cells infiltration with flow cytometry (t-SNE for subset dimensionality reduction) and immunofluorescence, and quantification of protein levels with Western blot. Liraglutide significantly alleviated pulmonary hemorrhage, as evidenced by reduced lung wet weight, incidence of lung hemorrhage, pulmonary hemosiderin-laden macrophages, and total serum IgG, without affecting body weight or glucose. Mechanistically, liraglutide treatment reduced pulmonary infiltration of multiple T and B lymphocyte subsets (e.g., CD4+, CD8+, B220+), while concurrently increasing alveolar macrophages and promoting M2 macrophage polarization. The phenotypic shift was demonstrated by increased M2 cell numbers, elevated CD206 expression, and downregulation of M1 marker CD86 and upregulation of M2 marker CD163 as confirmed at the protein level. Liraglutide treatment effectively ameliorates lupus-associated DAH, potentially through modulation of T cells, B cells, and macrophages polarization, offering a novel prophylactic and therapeutic strategy for this fatal complication of lupus.

Open article ↗



2025-09-30 | Diffuse alveolar hemorrhage in a child with mild hemophilia A who underwent bone marrow transplantation for thalassemia: a case report

Diffuse alveolar hemorrhage (DAH) is a relatively rare complication of bone marrow transplantation (BMT) associated with a high risk of mortality. It generally occurs in the early post-transplant phase during severe thrombocytopenia; however, since most thrombocytopenic cases do not develop DAH, cofactors are at play. Here, we discuss the case of a 4-year-old male child with mild asymptomatic hemophilia A discovered on routine evaluation pre-BMT, who developed DAH after a fully matched sibling BMT for HbE/Beta-thalassemia. The patient presented on day +21 post-BMT with sudden onset of cough followed one day later by hemoptysis. He had received FVIII supplementation with PTT normalization and FVIII levels of 28%. A chest CT scan showed interstitial lung disease with areas of ground glass bilaterally, mainly in the lower lobes. A radiological diagnosis of DAH was made, and the child was treated with additional FVIII concentrate (Advate), blow-by oxygen supplementation, red blood cells transfusion, platelet transfusion, methylprednisolone, tranexamic acid, and antioxidants (vitamin C and E). He responded well and recovered in a few days. Mild hemophilia associated with DAH post-BMT has never been reported before, however, it should be considered as a potentially treatable cause of DAH after BMT. FVIII levels should be part of the routine workup of children developing DAH post-transplantation. In the presence of thrombocytopenia, high FVIII levels of >30-40% might be required to prevent/treat DAH.

Open article ↗



2025-09-28 | Management and outcome of immune-mediated diffuse alveolar hemorrhage: a single centre case series

The standard treatment of immune-mediated diffuse alveolar hemorrhage (IM-DAH) encompasses immunosuppression with glucocorticoids (GC) and either cyclophosphamide (CYC) or rituximab (RTX). The role of intravenous immunoglobulin (IVIg) and plasma exchange (PLEX) remains controversial. We conducted a single-centre retrospective observational study on patients admitted with IM-DAH to evaluate treatment approaches and outcomes. Twelve episodes were identified in ten patients. All episodes were treated with GC and nine with CYC. IVIg was administered as first-line and/or bridging therapy in three cases with concomitant infections or high infection risk. PLEX was used in six episodes. IVIg and PLEX were primarily used as add-on therapies or when other immunosuppression was not recommended. After one year, nine patients survived. The combination of GC and CYC was the most common treatment regimen. While the role of PLEX and IVIg is not well established, they may be beneficial as second-line or as add-on therapies in selected cases.

Open article ↗



cell therapies
2024-11-19 | Trained mesenchymal stromal cell-based therapy HXB-319 for treating diffuse alveolar hemorrhage in a pristane-induced murine model.

Mesenchymal stromal cells (MSCs) can modulate immune responses and suppress inflammation in autoimmune diseases. Although their safety has been established in clinical trials, the efficacy of MSCs is inconsistent due to variability in potency among different preparations and limited specificity in targeting mechanisms driving autoimmune diseases. We utilized high-dimensional design of experiments methodology to identify factor combinations that modulate gene expression by MSCs to mitigate inflammation. This led to a novel MSC-based cell therapy, HXB-319. Its anti-inflammatory properties were validated in vitro by flow cytometry, RT-PCR, and mass spectrophotometry. To evaluate in vivo efficacy, we treated a diffuse alveolar hemorrhage (DAH) mouse model (C57Bl/6). Seven days post-DAH induction with pristane, mice received either MSCs or HXB-319 (2X106 cells, IP). On day 14, peritoneal lavage fluid (PLF) and lung tissue were collected for flow cytometry, histopathological examination, and mRNA. HXB-319 increased gene expression levels of anti-inflammatory, angiogenic, and anti-fibrotic factors (eg, TSG-6, VEGF, and HGF). KEGG pathway analysis confirmed significant activation of relevant anti-inflammatory, angiogenic, and anti-fibrotic proteins, corroborating RT-PCR results. In the DAH model, HXB-319 significantly reduced lung inflammation and alveolar hemorrhage compared to MSC-treated and untreated DAH mice. HXB-319 treatment also significantly decreased neutrophils, plasmacytoid dendritic cells, and RORγT cells, increased FoxP3+ cells in PLF, and reversed alterations in mRNA encoding IL-6, IL-10, and TSG-6 in lung tissue compared to DAH mice. HXB-319 effectively controls inflammation and prevents tissue damage in pristine-induced DAH, highlighting its therapeutic potential for autoimmune inflammatory diseases.

Open article ↗



2024-01-30 | The anti-inflammatory effects of mesenchymal stem cells attenuate diffuse pulmonary hemorrhage.

There are few effective treatment options for diffuse pulmonary hemorrhage (DPH). We aimed to elucidate the therapeutic role and underlying mechanisms of mesenchymal stem cells (MSCs) and MSC-derived extracellular vesicles (MSC-EVs) in DPH. Therapeutic effects of MSCs/MSC-EVs in pristane-induced DPH mice were evaluated via pulmonary function testing and histopathology. Transcriptome sequencing analyzed differentially expressed genes in control, DPH, and MSC groups. The proportion of macrophage polarization was evaluated in vivo and in vitro via fluorescence-activated cell sorting in control, DPH, MSC, MSC-EV inhalation, and MSC-EV intravenous groups. Intraperitoneal injection of pristane induced diffuse alveolar hemorrhage, early fibrosis, and inflammation in C57BL/6 mice. Monocytes were depleted in the peripheral blood in DPH mice and MSCs were recruited to the lungs, resulting in significantly attenuated diffuse alveolar hemorrhage and suppressed immunological response. This was more effective in the hyperacute hemorrhage phase than the early inflammatory phase. An MSC treatment-mediated anti-inflammatory effect was observed in DPH mice. Furthermore, MSC-EVs inhalation or tail-vein injection could effectively reduce DPH injury. MSCs could suppress macrophage M1 polarization in DPH in vivo and in vitro. MSCs displayed significant therapeutic effects in pristane-induced DPH, which may be a promising cell-free therapeutic approach.

Open article ↗



2023-01-24 | Updates in idiopathic pulmonary hemosiderosis in 2022: A state of the art review.

This manuscript reports the recent advances in idiopathic pulmonary hemosiderosis (IPH), a rare cause of diffuse alveolar hemorrhage in children and adults. This narrative review of the literature summarizes different aspects of IPH, including proposed pathogenesis, patient demographics, clinical and radiological characteristics, treatment, and prognosis. Additionally, the association between Celiac Disease (CD) and IPH is carefully evaluated. IPH is a frequently misdiagnosed disease. The delay in the diagnosis of IPH is often significant but fortunately, appears to have decreased in recent years. IPH in adults and children have distinct demographic preferences. The autoantibodies are common in IPH but with a definite difference between the adult and pediatric populations. The definitive diagnosis of IPH requires lung biopsy and careful exclusion of all competing diagnoses, even with lung biopsy showing bland pulmonary hemorrhage. The presence of nonspecific inflammatory cells or lymphoid aggregates may suggest a secondary immunologic phenomenon and needs careful evaluation and follow-up. A substantial number of patients suffer from coexisting CD, also known as Lane-Hamilton syndrome (LHS), and all patients with IPH need to be evaluated for LHS by serology. Although strict gluten free diet can manage the majority of patients with LHS, other patients generally require immunosuppressive therapy. The corticosteroids are the backbone of IPH therapy. Recently utilized experimental treatment options include mesenchymal stem cell transplant, liposteroid and bronchial artery embolization. The immunosuppression should be adjusted to achieve optimal disease control. Patients may progress to end-stage lung disease despite all measures, and lung transplantation may be the only viable option.

Open article ↗



2022-10-04 | Exosomes Derived from Human Umbilical Cord Mesenchymal Stem Cells Alleviate Diffuse Alveolar Hemorrhage Associated with Systemic Lupus Erythematosus in Mice by Promoting M2 Macrophage Polarization via the microRNA-146a-5p/NOTCH1 Axis.

Systemic lupus erythematosus (SLE)-associated diffuse alveolar hemorrhage (DAH) is a rare but extremely harmful condition. The current study sought to dissect the mechanisms underlying the effects of human umbilical cord mesenchymal stem cell (HUCMSC)-derived exosomes on M2 macrophage polarization in SLE-associated DAH via the microRNA (miR)-146a-5p/NOTCH1 axis. A DAH mouse model was established using pristane. Exosomes were isolated from HUCMSCs transfected or untransfected with the miR-146a-5p antagonist or agonist and their NCs and then injected into DAH mice. Additionally, miR-146a-5p was overexpressed in macrophages. Expression of miR-146a-5p, NOTCH1, M1 macrophage markers, and M2 macrophage markers was measured in mice and macrophages, and inflammatory factor levels were detected. Mouse lung injuries were evaluated, so was the binding of miR-146a-5p to NOTCH1. Rescue experiments were conducted in mice and macrophages using NOTCH1 shRNA and pcDNA3.1-NOTCH1, respectively. NOTCH1 expression was enhanced in DAH mice. HUCMSC-derived exosomes reduced NOTCH1 expression, bleeding, inflammation, and M1 macrophage polarization but elevated M2 macrophage polarization in lung tissues of DAH mice. Mechanistically, NOTCH1 is negatively targeted by miR-146a-5p. miR-146a-5p overexpression diminished M1 marker and inflammatory factor levels but enhanced M2 marker levels in macrophages, which was nullified by NOTCH1 overexpression. HUCMSC-derived exosomes with miR-146a-5p inhibition increased NOTCH1 expression, worsened bleeding and inflammation, and augmented M1 macrophage polarization while decreasing M2 macrophage polarization in lung tissues of DAH mice, which was abrogated by silencing NOTCH1. HUCMSC-derived exosomes diminished NOTCH1 expression to accelerate M2 macrophage polarization via delivery of miR-146a-5p, thus alleviating SLE-associated DAH in mice.

Open article ↗



2012-08-21 | Allogeneic transplantation of umbilical cord-derived mesenchymal stem cells for diffuse alveolar hemorrhage in systemic lupus erythematosus.

Umbilical cord-derived mesenchymal stem cell transplantation (UC-MSCT) has been proved to be effective in the treatment of systemic lupus erythematosus (SLE), based on animal experiments and clinical trials. Diffuse alveolar hemorrhage (DAH) is a rare complication of SLE with a high mortality usually over 50%. This study aimed to assess the efficacy of UC-MSCT in the treatment of SLE-associated DAH. Four SLE patients complicated with DAH, who underwent UC-MSCT, were included. Clinical changes before and after transplantation were assessed by measurements of hemoglobin, platelet level, oxygen saturation, and serological factors. High-resolution CT (HRCT) scans of the chest were performed to evaluate pulmonary manifestation. All the four patients showed dramatic improvements of their clinical manifestations. Hemoglobin was elevated after UC-MSCT and was sustained at a normal level 6 months after UC-MSCT in the four patients. Platelet level was upregulated in two patients who had thrombocytopenia at baseline. Oxygen saturation appeared to be normal at 1 month after UC-MSCT, and this result was confirmed by the HRCT scan of the chest. Serum albumin elevated to 3.5 g/dl 6 months after transplantation. Our findings suggest that UC-MSCT results in amelioration of oxygen saturation as well as hematological and serologic changes, which revealed that UC-MSCT could be applied as a salvage strategy for DAH patients.

Open article ↗



other
2022-08-26 | Down-regulated miR-146a expression with increased neutrophil extracellular traps and apoptosis formation in autoimmune-mediated diffuse alveolar hemorrhage

Increasing evidences have suggested an important role of microRNAs (miRNAs) in regulating cell death processes including NETosis and apoptosis. Dysregulated expression of miRNAs and increased formation of neutrophil extracellular traps (NETs) and apoptosis participate in autoimmune-mediated diffuse alveolar hemorrhage (DAH), mostly associated with pulmonary capillaritis in systemic lupus erythematosus (SLE) patients. In particular, besides the inhibition of apoptosis, miR-146a can control innate and acquired immune responses, and regulate the toll-like receptor pathway through targeting TRAF6 to reduce the expression of pro-inflammatory cytokines/chemokines like IL-8, a NETosis inducer.Expression of miR-146a, TRAF6 and NETs were examined in peripheral blood neutrophils (PBNs) and lung tissues from SLE-associated DAH patients, and in neutrophils and pristane-induced DAH lung tissues from C57BL/6 mice. To assess NETs formation, we examined NETosis-related DNAs morphology and crucial mediators including protein arginine deiminase 4 and citrullinated Histone 3. Expression of miR-146a and its endogenous RNA SNHG16 were studied in HL-60 promyelocytic cells and MLE-12 alveolar cells during NETosis and apoptosis processes, respectively. MiR-146a-overexpressed and CRISPR-Cas13d-mediated SNHG16-silenced HL-60 cells were investigated for NETosis. MiR-146a-overexpressed MLE-12 cells were analyzed for apoptosis. Pristane-injected mice received intra-pulmonary miR-146a delivery to evaluate therapeutic efficacy in DAH.In DAH patients, there were down-regulated miR-146a levels with increased TRAF6 expression and PMA/LPS-induced NETosis in PBNs, and down-regulated miR-146a levels with increased TRAF6, high-mobility group box 1 (HMGB1), IL-8, NETs and apoptosis expression in lung tissues. HMGB1-stimulated mouse neutrophils had down-regulated miR-146a levels with increased TRAF6, IL-8 and NETs expression. PMA-stimulated HL-60 cells had down-regulated miR-146a levels with enhanced NETosis. MiR-146a-overexpressed or SNHG16-silenced HL-60 cells showed reduced NETosis. Apoptotic MLE-12 cells had down-regulated miR-146a expression and increased HMGB1 release, while miR-146a-overexpressed MLE-12 cells showed reduced apoptosis and HMGB1 production. There were down-regulated miR-146a levels with increased TRAF6, HMGB1, IL-8, NETs and apoptosis expression in mouse DAH lung tissues. Intra-pulmonary miR-146a delivery could suppress DAH by reducing TRAF6, IL-8, NETs and apoptosis expression.Our results demonstrate firstly down-regulated pulmonary miR-146a levels with increased TRAF6 and IL-8 expression and NETs and apoptosis formation in autoimmune-mediated DAH, and implicate a therapeutic potential of intra-pulmonary miR-146a delivery.

Open article ↗



2021-06-28 | Targeting Intra-Pulmonary P53-Dependent Long Non-Coding RNA Expression as a Therapeutic Intervention for Systemic Lupus Erythematosus-Associated Diffuse Alveolar Hemorrhage

Diffuse alveolar hemorrhage (DAH) in systemic lupus erythematosus (SLE) is associated with significant mortality, requiring a thorough understanding of its complex mechanisms to develop novel therapeutics for disease control. Activated p53-dependent apoptosis with dysregulated long non-coding RNA (lncRNA) expression is involved in the SLE pathogenesis and correlated with clinical activity. We examined the expression of apoptosis-related p53-dependent lncRNA, including H19, HOTAIR and lincRNA-p21 in SLE-associated DAH patients. Increased lincRNA-p21 levels were detected in circulating mononuclear cells, mainly in CD4+ and CD14+ cells. Higher expression of p53, lincRNA-p21 and cell apoptosis was identified in lung tissues. Lentivirus-based short hairpin RNA (shRNA)-transduced stable transfectants were created for examining the targeting efficacy in lncRNA. Under pristane stimulation, alveolar epithelial cells had increased p53, lincRNA-p21 and downstream Bax levels with elevated apoptotic ratios. After pristane injection, C57/BL6 mice developed DAH with increased pulmonary expression of p53, lincRNA-p21 and cell apoptosis. Intra-pulmonary delivery of shRNA targeting lincRNA-p21 reduced hemorrhage frequencies and improved anemia status through decreasing Bax expression and cell apoptosis. Our findings demonstrate increased p53-dependent lncRNA expression with accelerated cell apoptosis in the lungs of SLE-associated DAH patients, and show the therapeutic potential of targeting intra-pulmonary lncRNA expression in a pristane-induced model of DAH.

Open article ↗



2016-03-28 | In Vivo Therapeutic Success of MicroRNA‐155 Antagomir in a Mouse Model of Lupus Alveolar Hemorrhage

Objective Diffuse alveolar hemorrhage (DAH) is a rare but life‐threatening complication of systemic lupus erythematosus (SLE). Pristane‐treated B6 mice develop severe DAH within 2 weeks of treatment. MicroRNA‐155 (miR‐155) is a pleiotropic microRNA that plays a crucial role in the regulation of immune responses. Recent studies have revealed a pathogenic role of miR‐155 in various autoimmune disorders. The purpose of this study was to examine the role of miR‐155 in the development of DAH in pristane‐induced lupus using miR‐155–knockout (miR‐155 −/− ) mice and miR‐155 antagomir to silence miR‐155. Methods DAH was induced by an intraperitoneal injection of 0.5 ml of pristane. MicroRNA‐155 antagomir was administered intravenously to silence miR‐155 expression. Lung tissues were collected for RNA extraction and were embedded in paraffin for sectioning. Gene expression profiling data were analyzed using Ingenuity Pathway Analysis. Real‐time quantitative polymerase chain reaction analysis was used for single‐gene validation. Luciferase reporter assay and argonaute 2 immunoprecipitation were performed for target validation. Results MicroRNA‐155 expression was significantly increased during the development of DAH. Disease progression was reduced in miR‐155 −/− mice as well as by in vivo silencing of miR‐155 using a miR‐155 antagomir. MicroRNA‐155 silencing dampened pristane‐induced ectopic activation of multiple inflammatory pathways and reduced the expression of proinflammatory cytokines. Several negative regulators of NF‐κB signaling were inhibited by pristane and were reactivated in miR‐155 −/− mice. In particular, the antiinflammatory factor peroxisome proliferator–activated receptor α was identified as a direct target of miR‐155. Conclusion MicroRNA‐155 promotes pristane‐induced lung inflammation. It contributes to ectopic activation of NF‐κB signaling pathways by targeting multiple negative regulators. MicroRNA‐155 antagomir may be a promising therapeutic strategy for treating acute lung inflammation in lupus.

Open article ↗



2008-10-01 | A NOVEL TREATMENT FOR RECURRENT DIFFUSE ALVEOLAR HEMORRHAGE ASSOCIATED WITH NON-MYELOABLATIVE ALLOGENIC STEM CELL TRANSPLANTATION

INTRODUCTION: Diffuse alveolar hemorrhage (DAH) occurs in about 5% of hematopoietic stem cell transplant (HSCT) recipients with a mortality rate of 30 – 70% (1Afessa B Tefferi A Litzow MR et al.Diffuse alveolar hemorrhage in hematopoietic stem cell transplant recipients.Am J Respir Crit Care Med. 2002; 166: 641-645Crossref PubMed Scopus (153) Google Scholar). We describe a patient with recurrent episodes of DAH occurring late in the post-HSCT course.

Open article ↗



Access all drug discovery papers and probability of success in trials forecasts:

Access all drug discovery papers and probability of success in trials forecasts:

Drug Discovery Landscape

2 orphan drug designations for Diffuse alveolar hemorrhage.

2 orphan drug designations for Diffuse alveolar hemorrhage.

Drug

Therapy type

Orphan designation

Clinical trial status

Sponsor

Recombinant coagulation factor VIIa

proteins

FDA
2006-04-26

—

Savara Inc.

Eptacog alfa (activated) [Newest7]

proteins

EMA
2005-12-14

—

[INACTIVE] Savara ApS

Explority AI logo

228 Park Ave S,
New York, USA.

At Explority, we build first-of-its-kind AI to bring clarity to the earliest and riskiest stages of pharmaceutical research by forecasting which therapies are most likely to succeed. Explority AI web and mobile applications are properties of the Explority AI Inc., a company registered in the United States (File No. 10320493).
For all questions: support@explority.ai

Copyright © 2026 Explority AI Inc.

Explority AI logo

228 Park Ave S,
New York, USA.

At Explority, we build first-of-its-kind AI to bring clarity to the earliest and riskiest stages of pharmaceutical research by forecasting which therapies are most likely to succeed. Explority AI web and mobile applications are properties of the Explority AI Inc., a company registered in the United States (File No. 10320493).
For all questions: support@explority.ai

Copyright © 2026 Explority AI Inc.

Explority AI logo

228 Park Ave S,
New York, USA.

At Explority, we build first-of-its-kind AI to bring clarity to the earliest and riskiest stages of pharmaceutical research by forecasting which therapies are most likely to succeed. Explority AI web and mobile applications are properties of the Explority AI Inc., a company registered in the United States (File No. 10320493).
For all questions: support@explority.ai

Copyright © 2026 Explority AI Inc.